MOXIFLOXACIN HYDROCHLORIDE Drug Patent Profile

When do Moxifloxacin Hydrochloride patents expire, and what generic alternatives are available?

Moxifloxacin Hydrochloride is a drug marketed by Alembic, Apotex, Epic Pharma Llc, Eugia Pharma, Fdc Ltd, Gland, Lupin, Mankind Pharma, Pharmobedient, Regcon Holdings, Somerset Theraps Llc, Upsher Smith Labs, Fresenius Kabi Usa, Aurobindo Pharma Ltd, Chartwell Rx, Crossmedika Sa, Dr Reddys, Hetero Labs Ltd V, Macleods Pharms Ltd, MSN, Natco, Sunshine, Teva Pharms Usa, Torrent, and Mylan Labs Ltd. and is included in twenty-six NDAs.

The generic ingredient in MOXIFLOXACIN HYDROCHLORIDE is moxifloxacin hydrochloride. There are eighteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the moxifloxacin hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Moxifloxacin Hydrochloride

A generic version of MOXIFLOXACIN HYDROCHLORIDE was approved as moxifloxacin hydrochloride by TEVA PHARMS USA on February 18^th, 2014.

Summary for MOXIFLOXACIN HYDROCHLORIDE

US Patents:	0
Applicants:	25
NDAs:	26
Finished Product Suppliers / Packagers:	32
Raw Ingredient (Bulk) Api Vendors:	105
Clinical Trials:	529
Patent Applications:	2,264
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MOXIFLOXACIN HYDROCHLORIDE
What excipients (inactive ingredients) are in MOXIFLOXACIN HYDROCHLORIDE?	MOXIFLOXACIN HYDROCHLORIDE excipients list
DailyMed Link:	MOXIFLOXACIN HYDROCHLORIDE at DailyMed

Recent Clinical Trials for MOXIFLOXACIN HYDROCHLORIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Research Insight LLC	PHASE4
Sanofi	PHASE1
Assiut University	PHASE3

See all MOXIFLOXACIN HYDROCHLORIDE clinical trials

Pharmacology for MOXIFLOXACIN HYDROCHLORIDE

Drug Class

Quinolone Antimicrobial Fluoroquinolone Antibacterial

Anatomical Therapeutic Chemical (ATC) Classes for MOXIFLOXACIN HYDROCHLORIDE

J01MA	Fluoroquinolones
J01M	QUINOLONE ANTIBACTERIALS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AE	Fluoroquinolones
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for MOXIFLOXACIN HYDROCHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MOXEZA	Ophthalmic Solution	moxifloxacin hydrochloride	0.5%	022428	1	2012-02-29
VIGAMOX	Ophthalmic Solution/Drops	moxifloxacin hydrochloride	0.5%	021598	1	2005-12-22

US Patents and Regulatory Information for MOXIFLOXACIN HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alembic	MOXIFLOXACIN HYDROCHLORIDE	moxifloxacin hydrochloride	SOLUTION/DROPS;OPHTHALMIC	209469-001	Feb 13, 2019	AT1	RX	No	No
Dr Reddys	MOXIFLOXACIN HYDROCHLORIDE	moxifloxacin hydrochloride	TABLET;ORAL	076938-001	Mar 4, 2014	AB	RX	No	Yes
Teva Pharms Usa	MOXIFLOXACIN HYDROCHLORIDE	moxifloxacin hydrochloride	TABLET;ORAL	077437-001	Feb 18, 2014	AB	RX	No	No

Market Dynamics and Financial Trajectory for Moxifloxacin Hydrochloride

Last updated: February 19, 2026

What is the Market Size and Growth Potential for Moxifloxacin Hydrochloride?

Moxifloxacin hydrochloride, a broad-spectrum fluoroquinolone antibiotic used to treat bacterial infections, faces a competitive landscape characterized by evolving regulatory policies, generics entry, and shifts in prescribing practices.

Global Market Size (2022):

• Estimated at USD 550 million.
• Projected Compound Annual Growth Rate (CAGR, 2023–2028): 2.5% to 4%.
• Driven by increasing bacterial resistance to older antibiotics and expanding indications, including respiratory, skin, and intra-abdominal infections.

Regional Breakdown (2022):	Region	Market Percentage	Notes
North America	40%	Led by U.S. hospital and outpatient demand
Europe	25%	Growing use in outpatient settings
Asia-Pacific	20%	Rapidly expanding due to healthcare infrastructure growth
Rest of World	15%	Limited by affordability and regulation

How Does Pricing and Patent Status Influence Financial Trajectory?

Patent Status:

• Patent protection for brand-name formulations expired between 2018 and 2020 globally.
• Generics entered markets shortly thereafter, reducing average price by 60–70%.

Pricing Trends:

• Branded Moxifloxacin: USD 3–5 per dose.
• Generics: USD 0.50–1.50 per dose.

Impact on Revenue:

• Revenue decline primarily from generics penetration.
• Still lucrative in emerging markets with higher prescribing rates and fewer generics.

Who Are the Key Market Players and Their Strategies?

Company	Market Share (Estimated, 2022)	Strategy
Bayer (Avelox)	50%	Continued expansion in developed markets, portfolio differentiation
Sandoz	20%	Focus on cost leadership, aggressive pricing
Teva	15%	Broaden distribution channels, increase access in emerging economies
Others	15%	Local manufacturers and niche marketing campaigns

What R&D and Regulatory Trends Shape the Market?

• Accelerated approvals for combination therapies and new indications.
• Focus on developing formulations with improved bioavailability and reduced resistance potential.
• Regulatory agencies (FDA, EMA) favor generics but demand stricter bioequivalence and safety data.

How Will Market Dynamics Affect Financial Performance?

Factor	Effect on Financials
Patent expirations	Leads to revenue decline from brand formulations, rise in generic sales
Pricing pressure	Reduces profit margins, especially in mature markets
Increased competition from biosimilars and generics	Drives down prices, diminishes revenue per unit
Expanded indications and new formulations	May offset declines, create new revenue streams

What Are the Future Revenue Drivers?

• Entry of combination products integrating Moxifloxacin with other antibiotics or therapeutic agents.
• Introduction of reformulations or delivery methods with improved compliance profiles.
• Growth in markets with rising bacterial infection incidence and less stringent patent enforcement.

Key Takeaways

• The global market for Moxifloxacin hydrochloride was USD 550 million in 2022, with slow-to-moderate growth expected through 2028.
• Patent expiries and generic competition have led to significant price erosion and revenue decline.
• North America and Europe comprise the majority of revenue, though Asia-Pacific presents growth opportunities due to healthcare expansion.
• Strategic focus on reformulations, new indications, and combination products could offset losses from patent expirations.
• Regulatory policies favor generic entry but require quality and bioequivalence standards.

FAQs

1. What factors could accelerate growth in the Moxifloxacin market?
Expansion of indications, improved formulations, and increased use in emerging markets.

2. How vulnerable is the market to generic competition?
Highly vulnerable; generic entry has reduced average prices and margins.

3. Are there upcoming regulatory hurdles?
Regulatory agencies are increasing bioequivalence and safety requirements, possibly delaying new formulations’ approvals.

4. Which regions offer the greatest revenue potential?
Asia-Pacific, due to market growth and less saturated competition, offers significant upside.

5. Will new formulations or combination therapies sustain profitability?
Yes, if they demonstrate clinical advantages and gain regulatory approval, they can sustain or grow revenue streams.

References

1. MarketResearch.com. (2023). Global Fluoroquinolone Antibiotics Market Report.
2. IQVIA. (2022). Prescription Trends and Market Share Data.
3. United States Food and Drug Administration. (2022). Bioequivalence Guidelines for Generic Drugs.
4. European Medicines Agency. (2022). Regulations on Antibiotic Approvals and Generic Entry.
5. ReportLinker. (2023). Latin America and Asia-Pacific Pharmaceutical Markets Overview.